2024
Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR-T therapies in autoimmunity
Bodansky A, Yu D, Rallistan A, Kalaycioglu M, Boonyaratanakornkit J, Green D, Gauthier J, Turtle C, Zorn K, O'Donovan B, Mandel-Brehm C, Asaki J, Kortbawi H, Kung A, Rackaityte E, Wang C, Saxena A, de Dios K, Masi G, Nowak R, O'Connor K, Li H, Diaz V, Saloner R, Casaletto K, Gontrum E, Chan B, Kramer J, Wilson M, Utz P, Hill J, Jackson S, Anderson M, DeRisi J. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR-T therapies in autoimmunity. Journal Of Clinical Investigation 2024, 134: e180012. PMID: 38753445, PMCID: PMC11213466, DOI: 10.1172/jci180012.Peer-Reviewed Original ResearchB-cell maturation antigenImmunomodulatory therapyPlasma cell-targeted therapyCAR-T therapyCell-targeted therapyAutoantibody mediated diseasesCAR-TAnti-CD19Maturation antigenAutoantibody profileAutoreactive antibodiesTargeted therapyPlasma cellsAutoimmune diseasesAutoantibody repertoireTherapyMediated diseasesAutoantibodiesTherapeutic interventionsProteome-wideDisease statesDiseaseImmunological fingerprintPhIP-SeqMinimal effect
2023
Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology
Pham M, Masi G, Patzina R, Obaid A, Oxendine S, Oh S, Payne A, Nowak R, O’Connor K. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathologica 2023, 146: 319-336. PMID: 37344701, PMCID: PMC11380498, DOI: 10.1007/s00401-023-02603-y.Peer-Reviewed Original ResearchConceptsMyasthenia gravisAntigenic modulationPathogenic mechanismsAutoimmune myasthenia gravisCurrent therapeutic approachesΑ-bungarotoxin bindingNicotinic acetylcholine receptorsReceptor blockadeSerum autoantibodiesAutoreactive clonesMonoclonal levelTherapeutic approachesMonoclonal autoantibodiesAcetylcholine receptorsComplement activationAutoantibodiesAChR subunitsJurkat cell lineDistinct molecular mechanismsPathogenic profilePathogenic capacityPathologyCell-based assaysMAbsPatientsUnearthing the Rosetta Stone of public antibody responses.
Masi G. Unearthing the Rosetta Stone of public antibody responses. Science Immunology 2023, 8: eadi4342. PMID: 37146131, DOI: 10.1126/sciimmunol.adi4342.Peer-Reviewed Original ResearchClinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
Masi G, Pham M, Karatz T, Oh S, Payne A, Nowak R, Howard J, Guptill J, Juel V, O'Connor K. Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis. Annals Of Clinical And Translational Neurology 2023, 10: 825-831. PMID: 36924454, PMCID: PMC10187728, DOI: 10.1002/acn3.51761.Peer-Reviewed Original Research
2022
Novel pathophysiological insights in autoimmune myasthenia gravis
Masi G, O’Connor K. Novel pathophysiological insights in autoimmune myasthenia gravis. Current Opinion In Neurology 2022, 35: 586-596. PMID: 35942663, PMCID: PMC9458626, DOI: 10.1097/wco.0000000000001088.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAutoimmune myasthenia gravisMyasthenia gravisMG patientsClinical responseMuscle-specific tyrosine kinaseSpecific therapeutic strategiesNovel pathophysiological insightsMG pathologyMG subtypesAutoantibody repertoireTreatment optionsCancer immunotherapyPredictive biomarkersSuch therapyImmunological heterogeneityPathophysiological insightsMG phenotypeTherapeutic strategiesClinical observationsTherapeutic outcomesAcetylcholine receptorsDisease subtypesTherapeutic perspectivesSubtypesDevelopment of assaysThe clinical need for clustered AChR cell-based assay testing of seronegative MG
Masi G, Li Y, Karatz T, Pham MC, Oxendine SR, Nowak RJ, Guptill JT, O'Connor KC. The clinical need for clustered AChR cell-based assay testing of seronegative MG. Journal Of Neuroimmunology 2022, 367: 577850. PMID: 35366559, PMCID: PMC9106915, DOI: 10.1016/j.jneuroim.2022.577850.Peer-Reviewed Original ResearchConceptsSNMG patientsMyasthenia gravisAChR-specific B cellsClinical needAcetylcholine receptor autoantibodiesSeronegative MG patientsSeronegative myasthenia gravisCell-based assaysAutoantibody positivityTrial eligibilityMG patientsReceptor autoantibodiesPatientsB cellsU.S. CentersNew treatmentsAssaysGravisAutoantibodiesSerostatusAChRPositivityClinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia.
Damato V, Papi C, Spagni G, Evoli A, Silvestri G, Masi G, Sabatelli E, Campetella L, McKeon A, Andreetta F, Riso V, Monte G, Luigetti M, Primiano G, Calabresi P, Iorio R. Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia. Eur J Neurol 2022, 29: 564-572. PMID: 34710286, DOI: 10.1111/ene.15161.Peer-Reviewed Original Research
2021
GABA-cadabra: autoantibodies trick neurotransmitter receptors and induce seizures.
Masi G, O'Connor KC. GABA-cadabra: autoantibodies trick neurotransmitter receptors and induce seizures. Science Immunology 2021, 6: eabn3790. PMID: 34860582, DOI: 10.1126/sciimmunol.abn3790.Peer-Reviewed Original ResearchAssessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis.
Masi G, Spagni G, Campetella L, Monte G, Sabatelli E, Evoli A, Papi C, Iorio R. Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis. J Neuroimmunol 2021, 356: 577601. PMID: 33975245, DOI: 10.1016/j.jneuroim.2021.577601.Peer-Reviewed Original Research
2020
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology.
Iorio R, Damato V, Spagni G, Della Marca G, Vollono C, Masi G, Papi C, Campetella L, Monte G, Evoli A. Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology. Eur J Neurol 2020, 27: 2062-2071. PMID: 32412135, DOI: 10.1111/ene.14325.Peer-Reviewed Original Research
2019
Nine syndrome.
Giuffrè GM, Iorio R, Masi G, Frisullo G, Luigetti M. Nine syndrome. Acta Neurol Belg 2019, 119: 475-476. PMID: 31102181, DOI: 10.1007/s13760-019-01151-1.Peer-Reviewed Original ResearchParaneoplastic neurological syndromes.
Iorio R, Spagni G, Masi G. Paraneoplastic neurological syndromes. Semin Diagn Pathol 2019, 36: 279-292. PMID: 31253539, DOI: 10.1053/j.semdp.2019.06.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute cerebellar stroke and middle cerebral artery stroke exert distinctive modifications on functional cortical connectivity: A comparative study via EEG graph theory.
Vecchio F, Caliandro P, Reale G, Miraglia F, Piludu F, Masi G, Iacovelli C, Simbolotti C, Padua L, Leone E, Alù F, Colosimo C, Rossini PM. Acute cerebellar stroke and middle cerebral artery stroke exert distinctive modifications on functional cortical connectivity: A comparative study via EEG graph theory. Clin Neurophysiol 2019, 130: 997-1007. PMID: 31005052, DOI: 10.1016/j.clinph.2019.03.017.Peer-Reviewed Original Research
2017
Defining a functional network homeostasis after stroke: EEG-based approach is complementary to functional MRI.
Caliandro P, Reale G, Vecchio F, Iacovelli C, Miraglia F, Masi G, Rossini PM. Defining a functional network homeostasis after stroke: EEG-based approach is complementary to functional MRI. Brain 2017, 140: e71. PMID: 29112697, DOI: 10.1093/brain/awx271.Commentaries, Editorials and Letters